Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Clinical Guidelines Recommend NAFLD Screening for Obese Children

XTALKS VITALS NEWS

NAFLD

Though not necessarily damaging to health on its own, NAFLD can progress into nonalcoholic steatohepatitis (NASH), causing inflammation and serious scarring of the liver tissue.

Share this!

December 7, 2016 | by Sarah Hand, M.Sc.

New clinical practice guidelines developed by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), suggest that obese children between the ages of nine and 11 should be screened for non-alcoholic fatty liver disease (NAFLD). The guidelines were set forth in a paper published in the Journal of Pediatric Gastroenterology and Nutrition.

NAFLD is characterized by the accumulation of excess fat in the liver. The condition most often occurs in individuals who are overweight and have high cholesterol, though some people develop NAFLD without exhibiting any of the known risk factors.

Though not necessarily damaging to health on its own, NAFLD can progress into nonalcoholic steatohepatitis (NASH), causing inflammation and serious scarring of the liver tissue. This type of liver disease can even lead to cirrhosis, impacting the liver’s ability to function.



“[NAFLD] has rapidly evolved into the most common liver disease seen in the pediatric population and is a management challenge for the general pediatric practitioners, subspecialists, and health systems,” Dr. Miriam B. Vos of Emory University and Children’s Healthcare of Atlanta, and coworkers, write in the abstract for the paper. “In this guideline, the expert committee on NAFLD (ECON) reviewed and summarized the available literature, formulating recommendations to guide screening and clinical care of children with NAFLD.”

Recent research suggests that 0.7 percent of children aged two to four may have NAFLD, with that number jumping up to 38 percent of obese children and young adults. NAFLD has also surpassed other liver diseases as the most common cause of liver transplants in adult patients.

The NASPGHAN guidelines recommend that obese children are screened for NAFLD using an alanine aminotransferase (ALT) liver enzyme test. A liver biopsy may be needed to confirm a diagnosis, and lifestyle changes – such as a healthier diet and more physical activity – are the recommended treatment options for NAFLD.

These new guidelines have also been endorsed by the American Academy of Pediatrics. The hope is that these clinical guidelines will help physicians diagnose and manage NAFLD in pediatric patients, using evidence-based approaches and screening methods.


Keywords: NAFLD, Obesity, Pediatric Health


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.